EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways

Yu Bian, Han Wu, Weitao Jiang, Xue Kong, Yuting Xiong, Linghua Zeng, Feng Zhang, Jinglun Song, Chunlei Wang, Yang Yang, Xinyue Zhang, Yuning Zhang und 5 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Yu Bian und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology (National Key Laboratory of Frigid Zone Cardiovascular Diseases, the State-Province Key Laboratories of Biomedicine-Pharma…. Hauptthemen laut MEDLINE: Hyperlipidemias, TOR Serine-Threonine Kinases, Fatty Liver, Hypolipidemic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose As a chronic metabolic syndrome, hyperlipidaemia is manifested as aberrantly elevated cholesterol and triglyceride (TG) levels, primarily attributed to disorders in lipid metabolism. Despite the promising outlook for hyperlipidaemia treatment, the need persists for the development of lipid‐lowering agents with heightened efficiency and minimal toxicity. This investigation aims to elucidate the lipid‐lowering effects and potential pharmacodynamic mechanisms of Anti‐b, a novel low MW compound. Experimental Approach We employed high‐fat diet (HFD) in hamsters and mice or oleic acid (OA) in cultures of HepG2 cells and LO2 cells to induce hyperlipidaemia models. We administered Anti‐b to assess its therapeutic effects on dyslipidaemia and hepatic steatosis. We used western blotting, RNA sequencing, GO and KEGG analysis, oil red O staining, along with molecular docking and molecular dynamics simulation to elucidate the mechanisms underlying the effects of Anti‐b. Key Results Anti‐b exhibited a substantial reduction in HFD‐induced elevation of blood lipids, liver weight to body weight ratio, liver diameter and hepatic fat accumulation. Moreover, Anti‐b demonstrated therapeutic effects in alleviating total cholesterol (TC), TG levels, and lipid accumulation derived from OA in HepG2 cells and LO2 cells. Mechanistically, Anti‐b selectively bound to the mTOR kinase protein and increased mTOR thermal stability, resulting in downregulation of phosphorylation level. Notably, Anti‐b exerted anti‐hyperlipidaemia effects by modulating PPARγ and SREBP1 signalling pathways and reducing the expression level of mSREBP1 and PPARγ proteins. Conclusion and Implications In conclusion, our study has provided initial data of a novel low MW compound, Anti‐b, designed and synthesised to target mTOR protein directly. Our results indicate that Anti‐b may represent a novel class of drugs for the treatment of hyperlipidemia and hepatic steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperlipidemiasTOR Serine-Threonine KinasesFatty LiverHypolipidemic AgentsAnimalsHumansSterol Regulatory Element Binding Protein 1Signal TransductionMaleHep G2 CellsMicePPAR gammaMice, Inbred C57BLDiet, High-FatCricetinaeMesocricetus

Stichwörter der Autor:innen

Anti‐bPPARαhepatic steatosishyperlipidaemiamTOR

Substanzen

TOR Serine-Threonine KinasesSterol Regulatory Element Binding Protein 1PPAR gammaHypolipidemic AgentsSrebf1 protein, mousemTOR protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology (National Key Laboratory of Frigid Zone Cardiovascular Diseases, the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry…

ORCID-Profile: Baofeng Yang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Bian, Y., Wu, H., Jiang, W., Kong, X., Xiong, Y., Zeng, L., Zhang, F., Song, J., Wang, C., Yang, Y., Zhang, X., Zhang, Y., Pang, P., Duo, T., Wang, Z., Pan, T., & Yang, B. (2025). Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways. British Journal of Pharmacology. https://doi.org/10.1111/bph.17397

Vancouver

Bian Y, Wu H, Jiang W, Kong X, Xiong Y, Zeng L, et al. Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways. British Journal of Pharmacology. 2025. doi:10.1111/bph.17397

BibTeX
@article{Bian2025,
  author = {Bian, Yu and Wu, Han and Jiang, Weitao and Kong, Xue and Xiong, Yuting and Zeng, Linghua and Zhang, Feng and Song, Jinglun and Wang, Chunlei and Yang, Yang and Zhang, Xinyue and Zhang, Yuning and Pang, Ping and Duo, Tianqi and Wang, Zhuo and Pan, Tengfei and Yang, Baofeng},
  title = {Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17397}
}
Kostenlos starten →